RxSight, Inc. has developed a differentiated intraocular lens system that enables post-operative customization of vision, addressing a key limitation of conventional premium lenses. The unique Light Adjustable Lens (LAL) technology has driven steady revenue growth, though the company continues to manage net losses and cash flow deficits as it scales adoption in the premium cataract market. Financial discipline, capital raises, and expanded surgeon penetration remain essential milestones to move toward profitability amid litigation and supply chain risks.